0000950162-05-000088.txt : 20120629
0000950162-05-000088.hdr.sgml : 20120629
20050120172857
ACCESSION NUMBER: 0000950162-05-000088
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20050120
DATE AS OF CHANGE: 20050120
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: CAVAZZA CLAUDIO
CENTRAL INDEX KEY: 0001164803
FILING VALUES:
FORM TYPE: SC 13G/A
MAIL ADDRESS:
STREET 1: VIA SUDAFRICA 20
CITY: ROME ITALY
STATE: L6
ZIP: 00000
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000880771
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943116852
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-43408
FILM NUMBER: 05539533
BUSINESS ADDRESS:
STREET 1: 901 MARINER'S ISLAND BLVD.
STREET 2: SUITE 205
CITY: SAN MATEO
STATE: CA
ZIP: 94404
BUSINESS PHONE: 650-358-3456
MAIL ADDRESS:
STREET 1: 901 MARINER'S ISLAND BLVD.
STREET 2: SUITE 205
CITY: SAN MATEO
STATE: CA
ZIP: 94404
SC 13G/A
1
claudio3gano2-011905.txt
AMENDMENT NO. 2
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A2
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
SciClone Pharmaceuticals, Inc.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, No Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)
80862K104
--------------------------------------------------------------------------------
(CUSIP Number)
November 18, 2004
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
/ / Rule 13d-1(b)
/X/ Rule 13d-1(c)
/ / Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Paolo Cavazza
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Italy
--------------------------------------------------------------------------------
5. Sole Voting Power
497,815
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 4,930,941
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 497,815
-----------------------------------------------------
8. Shared Dispositive Power
4,930,941
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
5,428,756
--------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) / /
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
12.2%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
IN
--------------------------------------------------------------------------------
1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Claudio Cavazza
--------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group
(See Instructions) (a) / /
(b) / /
--------------------------------------------------------------------------------
3. SEC Use Only
--------------------------------------------------------------------------------
4. Citizenship or Place of Organization
Italy
--------------------------------------------------------------------------------
5. Sole Voting Power
384,615
-----------------------------------------------------
Number of 6. Shared Voting Power
Shares
Beneficially 4,447,372
-----------------------------------------------------
Owned by Each 7. Sole Dispositive Power
Reporting
Person With: 384,615
-----------------------------------------------------
8. Shared Dispositive Power
4,447,372
--------------------------------------------------------------------------------
9. Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,987
--------------------------------------------------------------------------------
10. Check box if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions) / /
--------------------------------------------------------------------------------
11. Percent of Class Represented by Amount in Row (9)
10.8%
--------------------------------------------------------------------------------
12. Type of Reporting Person (See Instructions)
IN
Item 1(a). Name of Issuer:
SciClone Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
901 Mariner's Island Boulevard, Suite 315, San Mateo, CA 94404
Item 2(a). Name of Person Filing:
This statement is filed on behalf of each of the following persons
(collectively, the "Reporting Persons")
(i) Paolo Cavazza
(ii) Claudio Cavazza
Item 2(b). Address of Principal Business Office:
(i)
Paolo Cavazza
Via Tesserete, 10
Lugano, Switzerland
(ii)
Claudio Cavazza
Via Sudafrica, 20
Rome, Italy 00144
Item 2(c). Citizenship:
(i) Paolo Cavazza is an Italian citizen.
(ii) Claudio Cavazza is an Italian Citizen.
Item 2(d). Title of Class of Securities:
Common Stock, no par value (the "Shares")
Item 2(e). CUSIP Number:
80862K104
Item 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person is a:
This Item 3 is not applicable
Item 4. Ownership:
Paolo Cavazza
(a) Amount beneficially owned: 5,428,756
(b) Percent of class: 12.2%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 497,815
(ii) shared power to vote or to direct
the vote: 4,930,941
(iii) sole power to dispose or to direct
the disposition of: 497,815
(iv) shared power to dispose or to direct
the disposition of: 4,930,941
Claudio Cavazza
(a) Amount beneficially owned: 4,831,987
(b) Percent of class: 10.8%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct
the vote: 384,615
(ii) shared power to vote or to direct
the vote: 4,447,372
(iii) sole power to dispose or to direct
the disposition of: 384,615
(iv) shared power to dispose or to direct
the disposition of: 4,447,372
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person:
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company:
Not Applicable
Item 8. Identification and Classification of Members of the Group:
Not Applicable
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certification:
By signing below, I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary
course of business and were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the issuer
of the securities and were not acquired and are not held in connection with
or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: January 20, 2005
Paolo Cavazza
By: /s/ Paolo Cavazza
------------------------------
Name: Paolo Cavazza
Dated: January 20, 2005
CLAUDIO CAVAZZA
By: /s/ Claudio Cavazza
------------------------------
Name: Claudio Cavazza